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Background: Adenocarcinoma of the periampullary region is associated with poor prognosis and new prognostic and
treatment predictive biomarkers are needed for improved treatment. Membranous expression of podocalyxin-like
1(PODXL), which is a cell-adhesion glycoprotein and stem cell marker, has been found to correlate with an aggressive
tumour phenotype and adverse outcome in several cancer types. The aim of the present study was to examine the
clinicopathological correlates, prognostic and predictive significance of tumour-specific PODXL expression in a
retrospective cohort of pancreatic and periampullary carcinoma, morphologically divided into intestinal type (I-type)
and pancreatobiliary type (PB-type) tumours.
Methods: Immunohistochemical expression of PODXL was analysed in tissue microarrays with primary tumours and a
subset of paired lymph node metastases from 175 patients operated with pancreaticoduodenectomy for periampullary
adenocarcinoma. Chi square test was applied to analyse the relationship between PODXL expression and
clinicopathological parameters. Kaplan Meier analysis and Cox regression models were applied to estimate
differences in 5-year overall survival (OS) and recurrence-free survival (RFS) in strata according to membranous and
non-membranous PODXL expression.
Results: Membranous PODXL expression was significantly higher in primary PB-type (49.5 %) as compared with I-type
(17.5 %) tumours. In PB-type tumours, PODXL expression was significantly associated with female sex (p = 0.005), location
to the pancreas (p = 0.005), and poor differentiation grade (p= 0.044). Membranous PODXL expression was significantly
associated with a reduced RFS (HR = 2.44, 95 % CI 1.10–5.44) and OS (HR = 2.32, 95 % CI 1.05–5.12) in I-type tumours and
with a reduced RFS (HR = 1.63, 95 % CI 1.07–2.49) but not OS in PB-type tumours. PODXL remained a significant
independent prognostic factor only in I-type tumours (HR = 5.12, 95 % CI 1.43–18.31 for RFS and HR = 7.31, 95 %
CI 2.12–25.16 for OS). Patients with I-type tumours displaying membranous PODXL expression had a significant
beneficial effect of adjuvant chemotherapy regarding 5-year OS.
Conclusion: Membranous expression of PODXL is significantly higher in PB-type than in I-type periampullary
adenocarcinomas and an independent factor of poor prognosis in the latter. The results further indicate a beneficial
effect of adjuvant chemotherapy on I-type tumours with membranous PODXL expression, suggesting the potential
utility of PODXL as a biomarker for improved treatment stratification of these patients.
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Adenocarcinoma of the periampullary region, including
tumours originating in the distal bile duct, pancreas, am-
pulla of Vater and the periampullary duodenum, are a het-
erogeneous group of neoplasms and despite advances in
surgery, radiotherapy, chemotherapy and targeted agents,
patients still suffer from a poor prognosis. The incidence
of these tumours has markedly increased over the past de-
cades and in 2012 pancreatic cancers of all types were the
seventh most common cause of cancer deaths, resulting in
330.000 deaths globally [1]. The overall 5-year survival is
5 %, all stages of the disease combined, and the median
survival has been reported to be 5–8 months [2–4]. There
are no early detection tests and most patients with local-
ized disease have no recognizable symptoms or signs,
resulting in late diagnosis in the majority of cases. Only15-
20 % of the tumours are resectable at presentation [5],
resectability often being limited by early local invasion of
the surrounding anatomical structures, such as mesenteric
arteries, or distant metastasis. There are two major mor-
phological types of periampullary adenocarcinomas, i.e.
pancreatobiliary (PB-type) adenocarcinomas (including
pancreatic cancer, distal bile duct cancer, and some of the
ampullary carcinomas) and intestinal type (I-type) periam-
pullary adenocarcinomas (including duodenal carcinoma
and some of the ampullary carcinomas). Morphological
type seems to provide more important prognostic infor-
mation in resected periampullary carcinoma than the
tumour origin, with PB-type tumours being associated
with significantly shorter survival rates than I-type tu-
mours [6, 7]. The present diagnostic and prognostic infor-
mation provided by histopathological parameters is far
from sufficient, strongly implicating the need for add-
itional molecular-based biomarkers to better define clinic-
ally relevant subgroups of these tumours for improved
treatment stratification.
Podocalyxin-like protein (PODXL) is a member of the
CD34 family of transmembrane sialomucins. PODXL is
expressed on the apical surface of glomerular epithelial
cells and podocytes [8], where it plays an integral role in
maintaining adequate filtration [9], and it is also expressed
on vascular endothelia [10] and hematopoietic stem cells
[11, 12]. PODXL is upregulated in several types of cancer,
and strong expression, in particular in the cell membrane,
has been demonstrated to signify more aggressive tu-
mours and poor prognosis in e.g. breast cancer [13], colo-
rectal cancer [14-17] ovarian cancer [18], urinary bladder
cancer [19], and glioblastoma [20].
PODXL has been found to be more frequently expressed
(44 %) in pancreatic ductal adenocarcinoma as compared
with other types of adenocarcinomas of the gastrointestinal
and biliary tracts [21]. In another study, sialofucosylated
PODXL was demonstrated to be a functional E- and L-
selectin ligand expressed by metastatic pancreatic cancercells in vitro, and was also found to be overexpressed, with
membranous localization, in 69 % of 105 pancreatic ductal
adenocarcinomas [22]. To our knowledge, the prognostic
or predictive impact of PODXL expression in pancreatic or
periampullary adenocarcinoma has not yet been described.
The aim of the present study was therefore to examine the
clinicopathological correlates, prognostic and predictive
significance of tumour-specific PODXL expression in a
retrospective cohort of pancreatic and periampullary




The study consists of a retrospective consecutive cohort
of 175 patients with primary periampullary adenocarcin-
omas, surgically treated with pancreaticoduodenectomy
at the University hospitals of Lund and Malmö, Sweden,
from January 1 2001 until December 31 2011 [23–25].
Out of 175 cases in the entire cohort, there were 110
pancreatobiliary-type and 65 intestinal-type adenocarcin-
omas. Survival data were collected from the Swedish
National Civil Register. Follow-up started at the date of
surgery and ended at death, at 5 years after surgery or at
December 31, 2013, whichever came first. Information
on neoadjuvant and adjuvant treatment and recurrence
was obtained from patient records.
All haematoxylin & eosin stained slides from all cases
were re-evaluated by one pathologist (JEL), blinded to the
original report and outcome. The decision on tumour ori-
gin and morphological type was based on several criteria,
as previously described [23].
The study has been approved by the Ethics Committee
of Lund University (ref nr 445/07).
Tissue microarray construction
Tissue microarrays (TMAs) were constructed using a
semi-automated arraying device (TMArrayer, Pathology
Devices, Westminister, MD, USA). A standard set of
three tissue cores (1 mm) were obtained from each of
the 175 primary tumours and from lymph node metasta-
ses from 105 of the cases, whereby one to three lymph
node metastases were sampled in each case. Paired
samples with non-malignant pancreatic tissue from the
resection specimens were also obtained from 50 of the
cases, using a standard set of two 1 mm tissue cores.
Immunohistochemistry and staining evaluation
For immunohistochemical analysis of PODXL expres-
sion, 4 μm TMA-sections were automatically pre-treated
using the PT Link system and then stained in an Auto-
stainer Plus (DAKO; Glostrup, Copenhagen, Denmark)
with the affinity-purified polyclonal, monospecific PODXL
antibody (HPA002110; Atlas Antibodies AB, Stockholm,
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within the Human Protein Atlas (HPA) project, has also
been used in and validated in several previous biomarker
studies on e.g. colorectal, bladder, pancreatic and testicular
cancer [14, 19, 22, 26]. The expression of PODXL was re-
corded as negative (0), weak cytoplasmic positivity in any
proportion of cells (1), moderate cytoplasmic positivity in
any proportion of cells (2), distinct membranous positivity
in < = 50 % of cells (3) and distinct membranous positivity
in >50 % of cells (4) as previously described [14-16, 19].
Staining of PODXL was evaluated by two independent
observers (MH and KJ) who were blinded to clinical and
outcome data. Scoring differences were discussed in order
to reach consensus.
Statistical analysis
Chi square test was applied to analyse the relationship
between PODXL expression and clinicopathological pa-
rameters. Two patients with PB-type adenocarcinomas
who had received neoadjuvant chemotherapy were ex-
cluded from the correlation and survival analyses. Three
additional patients were excluded from the survival ana-
lyses; two with I-type adenocarcinomas who died within
one month from surgery due to complications and one
with PB-type adenocarcinoma who emigrated 5 months
after surgery.
Kaplan Meier analysis and log rank test were applied
to estimate differences in 5-year overall survival (OS)
and recurrence-free survival (RFS) in strata according to
membranous and non-membranous PODXL expression.
Hazard ratios (HR) for death and recurrence within 5 years
were calculated by Cox regression proportional hazard´s
modelling in unadjusted analysis and in a multivariable
model adjusted for age, sex, T-stage, N-stage, differenti-
ation grade, lymphatic invasion, vascular invasion, peri-
neural invasion, infiltration in peripancreatic fat, resection
margins, tumour origin, and adjuvant chemotherapy. A
backward conditional method was used for variable selec-
tion in the adjusted model. To estimate the interaction
effect between adjuvant treatment and PODXL expression
in order to measure any possible difference in treatment
effect based on PODXL expression, the following inter-
action variable was constructed; any adjuvant treatment
(+/−) × PODXL (+/−).
All tests were two sided. P-values <0.05 were consid-
ered significant. All statistical analyses were performed
using IBM SPSS Statistics version 20.0 (SPSS Inc., Chicago,
IL, USA).
Results
PODXL expression in non-malignant pancreas, primary
tumours and lymph node metastases
Sample immunohistochemical images of PODXL expres-
sion are shown in Fig. 1. PODXL expression could beassessed in in 63/65 (96.9 %) primary I-type carcinomas
and 24/30 (80.0 %) lymph node metastases, and in 107/
108 (99.1 %) primary PB-type carcinomas and 63/75
(84.0 %) corresponding lymph node metastases. PODXL
expression could be assessed in 49/50 (98 %) paired
non-malignant samples, all displaying negative or very
weak PODXL expression in acini and ducts. The distri-
bution of PODXL expression in primary tumours and
metastases, which did not differ significantly, by histo-
logical subtype, is shown in Fig. 2. Membranous PODXL
expression was denoted in 11/63 (17.5 %) primary and
2/24 (8.3 %) metastatic I-type carcinomas, and in 53/107
(49.5 %) primary and 23/63 (36.5 %) metastatic PB-type car-
cinomas. In I-type tumours, membranous PODXL in the
metastasis was seen in 1/21 (4.8 %) cases denoted as having
non-membranous expression in the primary tumour, and
non-membranous PODXL expression in the metastasis was
denoted in 2/3 (66.7 %) cases with primary tumours dis-
playing membranous PODXL expression. In PB-type tu-
mours, the number of cases with non-membranous to
membranous conversion was 2/32 (6.2 %) and with mem-
branous to non-membranous conversion 10/31 (32.3 %). In
all further statistical analyses, a dichotomized variable of
non-membranous (score 0, 1, 2) versus membranous (score
3, 4) PODXL expression in the primary and/or metastatic
component is applied. According to this combined variable,
12/63 (19.0 %) I-type cases and 55/107 (51.4 %) PB-type
cases displayed membranous PODXL expression in any
component.
Associations of PODXL expression with
clinicopathological factors
The associations between PODXL expression and clini-
copathological factors in I-type and PB-type tumours, re-
spectively, are shown in Table 1. In I-type tumours, there
were no significant associations between PODXL ex-
pression and clinicopathological factors. In PB-type tu-
mours, membranous PODXL expression was significantly
associated with female sex (p = 0.005), with location to the
pancreas (p = 0.005), and with poor differentiation grade
(p = 0.044). There was no statistically significant association
between PODXL expression and other clinicopathological
factors including age at diagnosis, tumour size, T-stage, N-
stage, resection margins, presence of vascular- lymphatic
and neural invasion and growth in peripancreatic fat.
Prognostic and potential predictive value of PODXL
expression
As demonstrated in Fig. 3, Kaplan-Meier analysis revealed
significant associations of membranous PODXL expres-
sion with a reduced RFS (logrank p = 0.024) and OS (log-
rank p = 0.032) in I-type tumours and with a reduced RFS
(logrank p = 0.022) but not OS in PB-type tumours. These
associations were confirmed in univariable Cox regression
Fig. 1 Sample immunohistochemical images. Immunohistochemical images of PODXL- negative non-malignant pancreatic tissue from two cases (top row),
primary intestinal-type (I-type) tumours (left column), primary pancreatobiliary-type (PB-type) tumours (mid-column) and metastases (right column) with different
PODXL staining scores (0–4). Asterisks indicate paired samples; i.e. from the same case/resection specimen. Score 0 = negative staining, score 1 =weak
cytoplasmic positivity in any proportion of cells, score 2: moderate-strong cytoplasmic positivity in any proportion of cells, score 3: distinct membranous
positivity in < = 50 % of cells and score 4 = distinct membranous positivity in >50 % of cells. All images with 10X original magnification
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tumours (HR = 2.44, 95 % CI 1.10–5.44, and HR = 2.32,
95 % CI 1.05–5.12, respectively) and for RFS (Table 2), butnot OS (Table 3) in PB-type tumours (HR = 1.63, 95 % CI
1.07–2.49, logrank p = 0.022). In multivariable analysis,
PODXL remained a significant prognostic factor only in
Fig. 2 PODXL expression in primary tumours and metastases
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Table 2, and HR= 7.31, 95 % CI 2.12–25.16 for OS, Table 3).
Next, we examined the potential predictive impact of
PODXL expression on survival in strata according to
adjuvant treatment. As demonstrated in Fig. 4, patients
with I-type tumours displaying membranous PODXL
expression had a significant beneficial effect of adjuvant
chemotherapy regarding 5-year OS. When ampullary PB-
type tumours, expressing membranous PODXL in a simi-
lar proportion to I-type tumours, were included in the
analysis, the beneficial value of adjuvant chemotherapy
was even more pronounced (Fig. 4). Hazard ratios for 5-
year OS according to adjuvant treatment and PODXL
expression are shown in Additional file 1. The results
demonstrate that survival did not differ significantly by
membranous PODXL-expression in patients with I-type
tumours or the extended group of I-type + ampullary PB-
type tumours having received adjuvant chemotherapy. In
contrast, the adverse prognostic impact of membranous
PODXL expression was even more evident in patients not
receiving adjuvant chemotherapy compared to the entire
group (unadjusted HR = 4.38, 95 % CI 1.57–12.18 in I-type
tumours, and unadjusted HR = 7.13; 95 % CI 2.64–19.26 in
I-type + ampullary PB-type tumours). These associations
remained significant in multivariable analysis, but there
was no significant treatment interaction (Additional file 1).
These associations were not significant in relation to RFS
(data not shown) or in PB-type tumours (data not shown).
The prognostic and predictive impact of membranous
PODXL expression was similar when only its expression in
the primary tumour was considered (data not shown). The
prognostic value of the full range of PODXL scores (0–4)
in relation to RFS and OS, in the entire cohort and by mor-
phological subtype, is shown in Additional file 2. All sur-
vival analyses were also performed using a dichotomizedvariable of score 0–1 vs 2–4, with allover less significant
results (data not shown).
Discussion
Pancreatic cancer is an extremely lethal type of cancer.
On average, patients die from the disease within 6 months
from diagnosis. Therefore it is of uttermost importance to
find both predictive and prognostic factors so as to im-
prove treatment. The results from this study provide a first
demonstration of the prognostic and potential predictive
value of PODXL in pancreatic, distal bile duct, ampullary
and duodenal adenocarcinoma. PODXL-expression was
found to be significantly higher in PB-type as compared
with I-type tumours, with the exception for ampullary PB-
type tumours. These findings are in line with the expected
and provide further evidence of PODXL being associated
with a more aggressive tumour phenotype and a biomarker
of poor prognosis in human cancer.
The study cohort encompasses a retrospective cohort
of 110 pancreatobiliary-type and 65 intestinal-type adeno-
carcinomas, including paired normal tissue and lymph
node metastases from a subset of cases, thus providing a
thorough characterization of PODXL expression in a wide
range of periampullary adenocarcinomas. In the present
study, membranous PODXL expression was denoted in
49.5 % of primary PB-type carcinomas, which is somewhat
lower than in the previous study by Dallas et al., including
tumours from 105 cases assembled in TMAs, wherein
membranous PODXL expression was found in 69 % of the
cases [22]. In primary I-type carcinomas, membranous
PODXL expression was denoted in 17.5 %, which is well
in line with previous TMA-based studies on colorectal
cancer wherein membranous expression was found in
13.4 % and 9.6 % respectively [14, 15]. This observation
further supports the theory that I-type carcinomas of the
Table 1 Associations between membranous and non-membranous PODXL expression with clinciopathological parameters in intestinal
type and pancreatobiliary type tumours, respectively
Intestinal type Pancreatobiliary type
PODXL NM PODXL M P PODXL NM PODXL M P
(n = 51) (n = 12) (n = 52) (n = 55)
Age
(median, range) 66.0 (38.0–83.0) 67.5 (44.0–74.0) 0.972 66.0 (44.0–81.0) 68.0 (44.0–81.0) 0.613
Sex
Women 28 (82.4) 6 (17.6) 0.761 17 (34.0) 33 (66.0) 0.005
Men 23 (79.3) 6 (20.7) 35 (61.4) 22 (38.6)
Tumour origin
Duodenum 12 (85.7) 2 (14.3) 0.610
Ampulla intestinal type 39 (79.6) 10 (20.4)
Ampulla pancreatobiliary type 14 (73.7) 5 (26.3) 0.005
Distal bile duct 23 (51.1) 22 (48.9)
Pancreas 15 (34.9) 28 (65.1)
Tumour size mm
(median, range) 30.0 (5.0–90.0) 26.5 (12.0–40.0) 0.923 30.0 (5.0–70.0) 30.0 (15.0–70.0) 0.313
Differentiation grade
Well-moderate 26 (83.9) 5 (16.1) 0.565 24 (61.5) 15 (38.5) 0.044
Poor 25 (78.1) 7 (21.9) 28 (41.2) 40 (58.8)
T-stage
T1 4 (100.0) 0 (0.0) 0.246 2 (100.0) 0 (0.0) 0.392
T2 9 (81.8) 2 (18.2) 4 (40.0) 6 (60.0)
T3 21 (84.0) 4 (16.0) 34 (43.6) 44 (56.4)
T4 17 (73.9) 6 (26.1) 12 (70.6) 5 (29.4)
N-stage
N0 28 (84.8) 5 (5.2) 0.936 17 (56.7) 13 (43.3) 0.315
N1 13 (68.4) 6 (31.6) 21 (46.7) 24 (53.3)
N2 10 (90.9) 1 (9.1) 14 (43.8) 18 (56.2)
Margins
R0 15 (88.2) 2 (11.8) 0.375 3 (50.0) 3 (50.0) 0.944
R1-Rx 36 (78.3) 10 (21.7) 49 (48.5) 52 (51.5)
Perineural growth
No 38 (86.4) 6 (13.6) 0.099 14 (63.6) 8 (36.4) 0.115
Yes 13 (68.4) 6 (31.6) 38 (44.7) 47 (55.3)
Invasion of lymphatic vessels
No 26 (89.7) 3 (10.3) 0.107 16 (50.0) 16 (50.0) 0.850
Yes 25 (73.5) 9 (26.5) 36 (48.0) 39 (52.0)
Invasion of blood vessels
No 48 (82.8) 10 (17.2) 0.217 35 (50.0) 35 (50.0) 0.691
Yes 3 (60.0) 2 (40.0) 17 (45.9) 20 (54.1)
Growth in peripancreatic fat
No 35 (85.4) 6 (14.6) 0.227 13 (59.1) 9 (40.9) 0.271
Yes 16 (72.7) 6 (27.3) 39 (45.9) 46 (54.1)
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Table 1 Associations between membranous and non-membranous PODXL expression with clinciopathological parameters in intestinal
type and pancreatobiliary type tumours, respectively (Continued)
Adjuvant chemotherapy
None 40 (88.9) 5 (11.1) 0.145 23 (46.0) 27 (54.0) 0.348
5-FU-analogue 2 (40.0) 3 (60.0) 5 (62.5) 3 (37.5)
Gemcitabine 4 (57.1) 3 (42.9) 20 (45.5) 24 (54.5)
Gemcitabine + capecitabine 1 (100.0) 0 (0.0) 1 (50.0) 1 (50.0)
Oxaliplatin + 5-FU analogue 4 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
Gemcitabine + oxaliplatin 0 (0.0) 1 (100.0) 2 (100.0) 0 (0.0)
M membranous PODXL expression, NM non-membranous PODXL expression
R0 radical resection, R1 non-radical resection, RX uncertain resection margins
Fig. 3 Survival according to membranous versus non-membranous PODXL expression. Kaplan-Meier estimates of recurrence free and 5-year overall
survival in patients with intestinal and pancreatobiliary type tumours, respectively. NM = non-membranous, M = membranous PODXL expression
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Table 2 Unadjusted and adjusted hazard ratios for recurrence within five years in intestinal and pancreatobiliary type tumours
Intestinal type Pancreatobiliary type
Unadjusted Adjusted Unadjusted Adjusted
n(events) HR(95 % CI) HR(95 % CI) n(events) HR(95 % CI) HR(95 % CI)
Age
Continuous 61 (29) 1.00 (0.96–1.03) 1.07 (1.02–1.13) 106 (88) 0.98 (0.96–1.01) 1.00 (0.96–1.03)
Gender
Female 34 (11) 1.00 1.00 50 (42) 1.00 1.00
Male 27 (18) 2.31 (1.08–4.94) 2.40 (0.94–6.14) 56 (46) 1.06 (0.70–1.61) 0.88 (0.53–1.49)
Tumour origin
Duodenum 13 (4) 1.00 1.00 _ _
Ampulla-Intestinal type 48 (25) 2.18 (0.76–6.27) 6.82 (1.32–35.12) _ _
Ampulla-Pancreatobiliary type _ _ 19 (16) 1.00 1.00
Distal Bile duct _ _ 44 (38) 1.10 (0.61–1.98) 1.52 (0.78–2.94)
Pancreas _ _ 43 (34) 1.06 (0.58–1.93) 0.93 (0.49–1.77)
Tumour size
Continuous 61 (30) 1.00 (0.98–1.02) 1.04 (1.00–1.09) 106 (88) 1.03 (1.02–1.05) 1.02 (0.99–1.04)
T-stage
T1 4 (1) 1.00 1.00 2 (1) 1.00 1.00
T2 10(3) 1.28 (0.13–12.30) 3.71 (0.34–40.64) 10 (6) 1.61 (0.19–13.36) 0.66 (0.07–6.08)
T3 25 (9) 1.86 (0.24–14.71) 5.72 (0.50–65.06) 77 (66) 4.67 (0.64–33.96) 1.21 (0.15–9.92)
T4 22 (16) 5.44 (0.72–41.21) 6.36 (0.21–195.20) 17 (15) 4.31 (0.56–33.10) 1.83 (0.08–40.27)
N-stage
N0 33 (11) 1.00 1.00 29 (21) 1.00 1.00
N1 (metastasis in 1–3 lgl) 19 (11) 2.07 (0.90–4.78) 1.00 (0.37–2.70) 45 (37) 2.17 (1.25–3.78) 2.04 (1.13–3.67)
N2 (metastasis in 4 or more lgl) 9 (7) 4.06 (1.55–10.59) 6.88 (1.81–26.15) 32 (30) 3.11 (1.72–5.61) 2.61 (1.42–4.83)
Differentiation grade
Well-moderate 30 (11) 1.00 1.00 39 (29) 1.00 1.00
Poor 31 (18) 2.16 (1.02–4.57) 1.38 (0.40–4.79) 67 (59) 2.32 (1.45–3.71) 2.02 (1.20–3.39)
Involved margins, status
R0 17 (3) 1.00 1.00 6 (4) 1.00 1.00
R1 & Rx 44 (26) 4.51 (1.36–14.94) 2.23 (0.62–8.03) 100 (84) 2.31 (0.84–6.36) 2.39 (0.84–6.76)
Lymphatic growth
Absent 28 (5) 1.00 1.00 32 (23) 1.00 1.00
Present 33 (24) 6.16 (2.34–16.19) 6.19 (1.76–21.82) 74 (65) 1.77 (1.09–2.88) 1.05 (0.59–1.85)
Vascular growth
Absent 56 (24) 1.00 1.00 70 (55) 1.00 1.00
Present 5 (5) 8.16 (2.86–23.30) 1.62 (0.39–6.65) 36 (33) 2.30 (1.47–3.61) 2.08 (1.28–3.36)
Perineural growth
Absent 42 (15) 1.00 1.00 22 (14) 1.00 1.00
Present 19 (14) 2.72 (1.31–5.66) 1.01 (0.27–3.81) 84 (74) 2.93 (1.57–5.46) 2.04 (1.06–3.90)
Growth in peripancreatic fat
Absent 40 (12) 1.00 1.00 22 (13) 1.00 1.00
Present 21 (17) 4.74 (2.23–10.10) 3.60 (1.43–9.07) 84 (75) 2.60 (1.42–4.75) 1.45 (0.76–2.77)
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Table 2 Unadjusted and adjusted hazard ratios for recurrence within five years in intestinal and pancreatobiliary type tumours
(Continued)
Adjuvant treatment
No 43 (21) 1.00 1.00 49 (40) 1.00 1.00
Yes 18 (8) 0.87 (0.38–1.96) 0.12 (0.04–0.44) 57 (48) 1.08 (0.70–1.65) 0.89 (0.54–1.49)
PODXL expression
Non-membranous 49 (20) 1.00 1.00 51 (40) 1.00 1.00
Membranous 12 (9) 2.44 (1.10–5.44) 5.12 (1.43–18.31) 55 (88) 1.63 (1.07–2.49) 1.53 (0.99–2.38)
R0 radical resection, R1 non-radical resection, RX uncertain resection margins
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in a stronger way than PB-types. In line with the study by
Ney et al., PODXL was negative or only weakly expressed
in normal pancreatic parenchyma from the resection spec-
imens [21].
In a previous study on colorectal cancer, wherein a
PODXL expression was compared in full-face sections
from 31 primary tumours and all available lymph node
metastases (n = 140), there was an excellent concordance
in that all primary tumours with non-membranous
PODXL expression had metastases with non-membranous
expression, whereas a few primary tumours with mem-
branous PODXL expression had a varying proportion of
metastatic lymph nodes with membranous and non-
membranous PODXL expression [16]. These findings led
to the conclusion that for prognostic or predictive pur-
poses, analysis of the primary tumour would be sufficient
[16]. In the present study, although negative conversion of
membranous PODXL expression from primary tumour to
lymph node metastasis was far more common than positive
conversion, a few cases displayed the latter phenomenon.
Of note, all analyses were based on TMA-samples, and
therefore, future studies based on full-face sections are
warranted to further examine the rate of positive conver-
sion of membranous PODXL expression in pancreatic and
periampullary cancers, so as to determine whether bio-
marker analysis of the primary tumour will be sufficient in
the clinical setting.
In the present study membranous PODXL expression
was an independent predictor of reduced 5-year overall
and recurrence-free survival in I-type but not in PB-type
tumours, although there was a significant association
between membranous PODXL expression and a reduced
RFS in the latter in unadjusted analysis. These findings
are well in line with previous publications regarding the
prognostic significance of PODXL expression in several
other major types of cancer [13–15, 18–20]. In addition,
and importantly, we found that patients with I-type tu-
mours displaying membranous PODXL had a beneficial
effect of adjuvant chemotherapy. When ampullary PB-
type tumours, expressing membranous PODXL in a simi-
lar proportion to I-type tumours, were included in the
analysis, the effect by adjuvant chemotherapy was evenmore pronounced. This supports earlier data that patients
with PODXL positive tumours benefit from adjuvant
chemotherapy, irrespective of treatment regime, as seen in
colorectal cancer [14, 15]. Moreover, these findings indi-
cate that I-type tumours with high expression of PODXL
are more likely to benefit from adjuvant therapy than PB-
type tumours. Today, all patients with pancreatic and peri-
ampullary adenocarcinoma are recommended adjuvant
treatment. Since adjuvant treatment often is associated
with toxicity and adverse side effects, it is important to
identify novel predictive and prognostic factors, such as
PODXL, to support and improve clinical decisions. There-
fore, the results from the present study indicate that
PODXL could be used as a predictive marker for adjuvant
treatment of periampullary cancer with intestinal morph-
ology, and possibly also ampullary PB-type tumours. Of
note, given the retrospective nature of the present study,
the term “predictive” should be applied with caution. It
must however be pointed out that the study cohort
encompasses a consecutive series of clinically and histo-
pathologically well-annotated pancreatoduodenectomy cases,
of which only approximately half have been given adjuvant
chemotherapy, which should allow for a fairly good assess-
ment of both prognostic and predictive biomarkers even
in the retrospective setting. Thus, the herein observed
prognostic and potential predictive value of PODXL, in
particular in I-type tumours, is of potential clinical rele-
vance and merits further study in additional retrospective
cohorts as well as in a controlled, prospective trial. Target-
ing PODXL with monoclonal antibodies may also be a
future treatment option [27].
Membranous PODXL expression was considerably higher
in PB-type as compared with I-type tumours, which is in
line with the former being clinically more aggressive. In
PB-type tumours, the prognostic value of PODXL was only
significant for RFS, and not after adjustment for other clin-
icopathological factors, and there was no evident predictive
value. The choice of prognostic cutoff, i.e. membranous vs
non-membranous PODXL expression, can be considered
appropriate for the herein used antibody, since the same
antibody and cutoff has been used in the previous study on
pancreatic cancer by Dallas et al. [22] and since this dichot-
omization yielded the strongest prognostic and predictive
Table 3 Unadjusted and adjusted hazard ratios for death within five years in intestinal and pancreatobiliary type tumours
Intestinal type Pancreatobiliary type
Unadjusted Adjusted Unadjusted Adjusted
n(events) HR(95 % CI) HR(95 % CI) n(events) HR(95 % CI) HR(95 % CI)
Age
Continuous 61 (30) 1.02 (0.98–1.06) 1.07 (1.02–1.13) 106 (82) 0.99 (0.96–1.02) 1.01 (0.98–1.05)
Gender
Female 34 (13) 1.00 1.00 50 (36) 1.00 1.00
Male 27 (17) 1.85 (0.89–3.84) 2.12 (0.86–5.22) 56 (46) 1.20 (0.78–1.87) 1.22 (0.76–1.95)
Tumour origin
Duodenum 13 (5) 1.00 1.00 _ _
Ampulla-Intestinal type 48 (25) 1.49 (0.57–3.88) 7.77 (1.86–32.39) _ _
Ampulla-Pancreatobiliary type _ _ 19 (16) 1.00 1.00
Distal Bile duct _ _ 44 (32) 0.74 (0.40–1.34) 1.03 (0.50–2.15)
Pancreas _ _ 43 (34) 0.91 (0.50–1.65) 1.06 (0.52–2.19)
Tumour size
Continuous 61 (30) 1.00 (0.98–1.03) 1.05 (1.01–1.10) 106 (82) 1.03 (1.01–1.05) 1.01 (0.99–1.04)
T-stage
T1 4 (2) 1.00 1.00 2 (1) 1.00 1.00
T2 10(3) 0.65 (0.11–3.88) 0.55 (0.07–4.50) 10 (6) 1.43 (0.17–11.85) 0.77 (0.08–7.56)
T3 25 (9) 0.94 (0.20–4.37) 1.49 (0.19–11.34) 77 (60) 2.95 (0.41–21.34) 0.84 (0.10–7.08)
T4 22 (16) 2.55 (0.58–11.15) 1.88 (0.19–18.25) 17 (15) 3.77 (0.50–28.71) 2.12 (0.09–48.78)
N-stage
N0 33 (15) 1.00 1.00 29 (18) 1.00 1.00
N1 (metastasis in 1–3 lgl) 19 (9) 1.17 (0.51–2.68) 0.55 (0.20–1.50) 45 (37) 2.41 (1.35–4.29) 2.85 (1.57–5.17)
N2 (metastasis in 4 or more lgl) 9 (6) 2.08 (0.80–5.37) 8.96 (2.47–32.51) 32 (27) 2.59 (1.40–4.78) 2.45 (1.30–4.63)
Differentiation grade
Well-moderate 30 (12) 1.00 1.00 39 (24) 1.00 1.00
Poor 31 (18) 1.98 (0.95–4.11) 2.16 (0.77–6.03) 67 (58) 2.44 (1.50–3.95) 2.13 (1.28–3.54)
Involved margins, status
R0 17 (4) 1.00 1.00 6 (2) 1.00 1.00
R1 & Rx 44 (26) 2.56 (0.89–7.36) 0.46 (0.12–1.69) 100 (80) 3.49 (0.86–14.25) 2.57 (0.62–10.60)
Lymphatic growth
Absent 28 (7) 1.00 1.00 32 (22) 1.00 1.00
Present 33 (23) 3.61 (1.55–8.44) 5.85 (1.93–17.77) 74 (60) 1.51 (0.92–2.48) 0.96 (0.55–1.70)
Vascular growth
Absent 56 (25) 1.00 1.00 70 (47) 1.00 1.00
Present 5 (5) 7.78 (2.74–22.11) 1.70 (0.40–7.31) 36 (35) 2.39 (1.54–3.72) 2.45 (1.54–3.87)
Perineural growth
Absent 42 (17) 1.00 1.00 22 (14) 1.00 1.00
Present 19 (13) 2.15 (1.04–4.44) 3.81 (1.55–9.37) 84 (68) 1.88 (1.05–3.38) 0.92 (0.48–1.76)
Growth in peripancreatic fat
Absent 40 (14) 1.00 1.00 22 (14) 1.00 1.00
Present 21 (16) 3.49 (1.68–7.25) 0.75 (0.06–9.94) 84 (68) 1.80 (1.00–3.25) 1.25 (0.64–2.43)
Adjuvant treatment
No 43 (24) 1.00 1.00 49 (39) 1.00 1.00
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Table 3 Unadjusted and adjusted hazard ratios for death within five years in intestinal and pancreatobiliary type tumours
(Continued)
Yes 18 (6) 0.60 (0.25–1.47) 0.03 (0.01–0.16) 57 (43) 0.90 (0.58–1.39) 0.67 (0.43–1.04)
PODXL expression
Non-membranous 49 (21) 1.00 1.00 51 (38) 1.00 1.00
Membranous 12 (9) 2.32 (1.05–5.12) 7.31 (2.12–25.16) 55 (44) 1.32 (0.85–2.03) 1.10 (0.67–1.81)
R0 radical resection, R1 non-radical resection, RX uncertain resection margins
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mours with moderate-strong cytoplasmic staining (score 2)
is a somewhat ambiguous group with an intermediate
prognosis, undoubtedly harbouring some cases with a
prognosis equally poor to cases with membranous PODXL
expression. While it is possible that in some of these cases,
the presence of membranous expression may be masked
by a strong cytoplasmic expression, this category of tu-
mours may also constitute a different biological entity, pos-
sibly constituting an “intermediate” between tumours with
negative/weak and membranous PODXL expression. In a
comparative study on colorectal cancer, membranous
expression of the herein used antibody and cytoplasmic
expression of an in-house generated antibody were both
found to be independent predictors of poor prognosis, and
combined use of the antibodies was found to detect a
group with an even worse prognosis [28].
Previous studies have demonstrated PODXL to be a
functional ligand of E- and L- selectins in pancreatic can-
cer suggesting that its expression may promote haemoto-
genic spread of metastases by facilitating binding ofFig. 4 Survival according to PODXL expression and adjuvant chemotherap
of membranous (M)/ non-membranous (NM) PODXL expression and adjuvan
tumours and intestinal type + ampullary pancreatobiliary type tumours, respecticirculating tumour cells to selectin-expressing host cells
[22]. These findings further support the theory of PODXL
overexpression being associated with more aggressive tu-
mours [22]. Moreover, similar to the situation in colorectal
[14, 15, 16] and urinary bladder [19] cancer, PODXL ex-
pression was observed predominantly on the invasive
tumour front, also suggesting its importance in the meta-
static spread of the disease. Of note, in the study on bladder
cancer, the herein used polyclonal antibody was compared
with two other monoclonal antibodies, all showing 100 %
concordance regarding the detection of membranous
PODXL expression, whereas the degree of cytoplasmic
expression detected by the monoclonal antibodies was
substantially weaker [19].
Our results are derived from TMA-based analyses on
retrospectively collected tumour samples. Of note, the
TMA-technique was also used in the study by Dallas et al.
[22]. For characterization of key molecular alterations and
expression of investigative biomarkers in tumours from
large patient cohorts, whether retrospectively or prospect-
ively defined, the TMA-technology is essential [29].y. Kaplan-Meier estimates of 5-year overall survival in combined strata
t (A) /no adjuvant (NA) chemotherapy in patients with intestinal type
vely. NM = non-membranous, M = membranous PODXL expression
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must be considered, most importantly its ability to accur-
ately reflect the expression of heterogeneously expressed
markers. To compensate for this one needs to ensure that
tumour cores are sampled from different regions of the
tumour. In the present study, the cores from the primary
tumour were, whenever possible, obtained from different
donor blocks, and different lymph nodes were sampled in
cases with more than one metastatic node.
Conclusions
Membranous expression of PODXL is significantly higher
in pancreatobiliary type as compared with intestinal type
periampullary adenocarcinomas and an independent factor
of poor prognosis in the latter. The herein presented results
also indicate a beneficial effect of adjuvant chemotherapy
on intestinal type tumours with membranous PODXL
expression, suggesting the potential utility of PODXL as a
biomarker for improved treatment stratification of these
patients.
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